Pulsatile induction of the p53 pathway by MDM2 antagonist ASTX295 shows an enhanced therapeutic index in vivoEUROPEAN JOURNAL OF CANCERIF7.12024-10-010PRE
Targeting the MDM2-p53 interaction: Time- and concentration-dependent studies in tumor and normal human bone marrow cells reveal strategies for an enhanced therapeutic indexCANCER RESEARCHIF16.62024-03-220PRE
Discovery of ASTX295, a potent, next-generation small molecule antagonist of MDM2 with differentiated pharmacokinetic profileCANCER RESEARCHIF16.62024-03-221PRE
Targeting Cytotoxic Agents through EGFR-Mediated Covalent Binding and ReleaseJOURNAL OF MEDICINAL CHEMISTRYIF6.82023-08-303OAAI
Modulation of ERK5 Activity as a Therapeutic Anti-Cancer StrategyJOURNAL OF MEDICINAL CHEMISTRYIF6.82023-04-0110OAAI
Simultaneous targeting of glycolysis and oxidative phosphorylation as a therapeutic strategy to treat diffuse large B-cell lymphomaBRITISH JOURNAL OF CANCERIF6.82022-05-2634OAAI
Parallel Optimization of Potency and Pharmacokinetics Leading to the Discovery of a Pyrrole Carboxamide ERK5 Kinase Domain InhibitorJOURNAL OF MEDICINAL CHEMISTRYIF6.82022-04-253OAAI
An Alkynylpyrimidine-Based Covalent Inhibitor That Targets a Unique Cysteine in NF-κB-Inducing KinaseJOURNAL OF MEDICINAL CHEMISTRYIF6.82021-07-029OAAI
DNAPK Inhibition Preferentially Compromises the Repair of Radiation-induced DNA Double-strand Breaks in Chronically Hypoxic Tumor Cells in Xenograft ModelsMOLECULAR CANCER THERAPEUTICSIF5.52021-06-227OAAI
Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Protein-Protein InteractionJOURNAL OF MEDICINAL CHEMISTRYIF6.82021-03-2435OA
Selective DNA-PKcs inhibition extends the therapeutic index of localized radiotherapy and chemotherapyJOURNAL OF CLINICAL INVESTIGATIONIF13.62019-11-2558OAAI
Identification of a novel orally bioavailable ERK5 inhibitor with selectivity over p38α and BRD4EUROPEAN JOURNAL OF MEDICINAL CHEMISTRYIF5.92019-09-0116OAAI
Highly Potent Clickable Probe for Cellular Imaging of MDM2 and Assessing Dynamic Responses to MDM2-p53 InhibitionBIOCONJUGATE CHEMISTRYIF3.92018-05-313PREAI
Differential Regulation of G1 CDK Complexes by the Hsp90-Cdc37 Chaperone SystemCELL REPORTSIF6.92017-10-0151OAAI
Ex vivo treatment of patient biopsies as a novel method to assess colorectal tumour response to the MEK1/2 inhibitor, SelumetinibSCIENTIFIC REPORTSIF3.92017-09-205OAAI
A novel, selective inhibitor of DNA-dependent protein kinase (DNA-PK) potentiates the effects of DNA-damaging therapies in hepatocellular carcinomaCANCER RESEARCHIF16.62017-07-010PRE
Inhibition of monocarboxyate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and Burkitt lymphomaHAEMATOLOGICAIF7.92017-04-06111OAAI
A minimum core outcome dataset for the reporting of preclinical chemotherapeutic drug studies: Lessons learned from multiple discordant methodologies in the setting of colorectal cancerCRITICAL REVIEWS IN ONCOLOGY HEMATOLOGYIF5.62017-04-015OAAI
Aurora A regulates expression of AR-V7 in models of castrate resistant prostate cancerSCIENTIFIC REPORTSIF3.92017-02-1634OAAI